Recently, using the VaxHit technology, Vaxil has isolated and developed novel proprietary antibodies against MUC1 SP epitopes.
The SPmAb2.1 and SPmAb-6 are the first ever antibodies produced against the signal peptide domain of the MUC1 tumor associated antigen. The isolation of antibodies targeting the signal peptide additional of other undisclosed targets is underway. Vaxil can isolate signal peptide (SP) epitopes that can be used as antigens for generating more specific antibodies against known and novel targets. Recently, the company isolated SPmAb2.1 and SPmAb-6, the first isolated, anti- MUC1 signal peptide-specific antibodies based on the unpredicted finding of tumor- associated, MHC- independence cell surface existence of MUC1 signal peptide epitopes. These findings are protected by broad patents coverage. More recently antibodies to other non-disclosed tumor antigen have been generated using VaxHit and validated the original findings around MUC1 signal peptide.